Description:Bamaciclib mesylate is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6, which play crucial roles in cell cycle regulation. This compound is utilized in the treatment of certain types of cancers, particularly hormone receptor-positive breast cancer, by inhibiting the proliferation of cancer cells. Bamaciclib mesylate is characterized by its ability to disrupt the cell cycle, leading to cell cycle arrest and apoptosis in malignant cells. The mesylate salt form enhances its solubility and bioavailability, making it more effective for therapeutic use. In terms of physical properties, it is typically presented as a white to off-white solid. The compound's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are essential for determining its efficacy and safety profile in clinical settings. As with many targeted therapies, monitoring for potential side effects and drug interactions is crucial during treatment. Overall, Bamaciclib mesylate represents a significant advancement in targeted cancer therapies, contributing to personalized medicine approaches in oncology.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-…](https://static.cymitquimica.com/products/IN/thumb/DA000K54.jpg)
